Dr. Zhang has good knowledge of regulatory requirements (cGMP and FDA). His strength of translating the application based market needs to R&D is outstanding, as well as developing strategic and tactical planning for product development. Technically, proven record of developing innovative solutions and practical implementations for iPSCs related regenerative cell biology research, biotherapeutic antibody development and characterisation in translational medicine.

1 Discovery of Cell Signalling mechanism and clinical use in degenerative disease

2 Instrumentation development for regenerative cell biology research and clinical application.

Dr Zhang joined GIBH in 2013 as a PI. He undertook several instrument development projects, and has developed the first instrument for hiPSC automated induction in the world. He have established the automation platform for cell culture, induction and differentiation， which will promote development of stem cell fundamental research and clinical application. Many patents have been applied base the automation system and Dr Zhang also have published several articles in relate research areas.

1. Ke Fan, Sheng Zhang, Ying Zhang,……, Xiao Zhang*. A Machine Learning Assisted, Label-free, Non-invasive Approach for Somatic Reprogramming in Induced Pluripotent Stem Cell Colony Formation Detection and Prediction. Sci Rep. 2017 Oct;7(1):13496

2. Songwei He,  Jinlong Chen,……, Xiao Zhang, Yiping Guo, Duanqing Pei,  Hui Zheng*. Sequential EMT-MET induces neuronal conversion through Sox2. Cell Discov. 2017 May; 3: 17017

3. Xiao Zhang, Gemma Montagut Pino, ……, Eva E. Qwarnstrom*. Distinct Control of MyD88 Adapter-dependent and Akt Kinase-regulated Responses by the Interleukin (IL)-1RI Co-receptor, TILRR. J Biol Chem. 2012 Apr ; 287(15): 12348–12352

4. Xiao Zhang, Freya Shephard, ……, Eva E. Qwarnstrom*. TILRR, a Novel IL-1RI Co-receptor, Potentiates MyD88. Recruitment to Control Ras-dependent Amplification of NF-κB. J Biol Chem. 2010 Mar ; 285(10): 7222–7232